Sign in
Taking peoplePhase 2

A Clinical Trial to Assess the Safety and PK of OMN6 in HABP or VABP Caused by Acinetobacter Baumannii Complex

Key facts

Who runs it
Omnix Medical Ltd
Where
Greece, Hungary, Israel, and Italy21 sites in 4 countriesChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 2
People taking part
54 people, planned
Started
14 May 2026
Expected to end
Mar 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • OMN6
  • Placebo
Record updated
28 September 2026

Who can take part

Age
18 years to 99 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • A signed informed consent form
  • Male or female patients 18 years or older
  • A diagnosis of either a HABP or a VABP
  • ABC infection of the lower respiratory tract suspected based on a positive rapid testing of respiratory specimens
  • Women of childbearing potential (WOCBP) (i.e., not post-menopausal or surgically sterilized) must have a negative highly sensitive urine or serum pregnancy test before randomization
  • Acute Physiology and Chronic Health Evaluation II (APACHE II) score between 10 and 24

Who cannot take part

  • Acute respiratory distress syndrome
  • Immunosuppressed patients (due to either immunosuppressant drugs or to any medical condition)
  • History of any known hypersensitivity to colistin or to carbapenems
  • Any condition or circumstance that, in the opinion of the investigator, would compromise the safety of the patient or the quality of the study data
  • Moderate to severe reduction of renal function
  • Liver dysfunction
  • Evidence of septic shock

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 99 years old?

This trial is currently available in Greece and Israel.

It has sites in 4 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a phase 2a, multinational, multicenter, double-blind, randomized, placebo-controlled, dose-ranging safety, tolerability and PK study in patients with HABP (Hospital Acquired Bacterial Pneumonia) or VABP (Ventilator Associated Bacterial Pneumonia) caused by ABC to identify safe and well-tolerated doses and to assess the PK profile of OMN6 in patients.

The 2 groups in the trial

  • OMN6 treatmentTreatment being tested

    OMN6 on top of Meropenem and Colistin

    Treatment: OMN6

  • PlaceboPlacebo, for comparison

    Placebo on top of Meropenem and Colistin

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Prospective, Multinational, Multicenter, Randomized, Sequential, Double-blind, Placebo-controlled, Phase 2a Clinical Trial to Assess the Safety and Pharmacokinetics of OMN6 in HABP or VABP Caused by Acinetobacter Baumannii Complex (ABC).
Criteria questions
Built from NCT06087536, who can take part
Record updated
28 September 2026